Advertisement

Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists

  • Colin Marshall
  • Maharshi A. Rajdev
  • Bhanusupriya Somarouthu
  • Nikhil H. Ramaiya
  • Francesco Alessandrino
Pictorial essay
  • 52 Downloads

Abstract

Imaging has a central role in surveillance of cervical cancer, guiding decision on when to initiate treatment for recurrent disease and to guide management in advanced cervical cancer. Due to the increased availability of pelvic radiation therapy, the rate of atypical presentation of recurrent disease has increased. Simultaneously, the array of systemic therapies now available for advanced cervical cancer has considerably expanded in the last few years, with therapies now available in mid and low-income countries. While pelvic recurrences are amenable of loco-regional treatment, recurrent disease may present with metastases to the thoracoabdominal organs, lymph nodes, bones, skin and brain, for which systemic treatment represent the standard of care. Besides combined chemotherapy regimens, alternative chemotherapies, biosimilars and immune checkpoint inhibitors are now available, each associated with a definite pattern of response and toxicity. In this review, after describing the typical and atypical presentations of recurrent and advanced cervical carcinoma on cross-sectional imaging, we will discuss systemic treatment for recurrent or advanced disease and their associated radiographic sequelae, in light of the newly available therapies.

Keywords

Uterine cervical neoplasms Neoplasm recurrence Neoplasm metastases Diagnostic imaging Antineoplastic agents Biosimilar pharmaceuticals 

Notes

Compliance with ethical standards

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Statement of informed consent is not applicable since the manuscript does not contain any patient data.

References

  1. 1.
    American Cancer Society. Global burden of cancer in women (2018) Current status, trends, and interventions. Atlanta: American Cancer Society; 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-burden-of-cancer-in-women.pdf. Accessed 18 July 2018
  2. 2.
    Adegoke O, Kulasingam S, Virnig B (2002) Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health 21(10):1031–1037CrossRefGoogle Scholar
  3. 3.
    Fagundes H, Perez CA, Grigsby PW, Lockett M (1992) Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol 24(2):197–204CrossRefGoogle Scholar
  4. 4.
    Elit L, Fyles AW, Devries MC, et al. (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114(3):528–535CrossRefGoogle Scholar
  5. 5.
    Peiretti M, Zapardiel I, Zanagnolo V, et al. (2012) Management of recurrent cervical cancer: a review of the literature. Surg Oncol 21(2):e59–e66CrossRefGoogle Scholar
  6. 6.
    Sreedevi A, Javed R, Dinesh A (2015) Epidemiology of cervical cancer with special focus on India. Int J Womens Health 7:405–414PubMedPubMedCentralGoogle Scholar
  7. 7.
    LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN (2017) Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery. Gynecol Oncol Rep 22:16–20CrossRefGoogle Scholar
  8. 8.
    Charakorn C, Thadanipon K, Chaijindaratana S, et al. (2018) The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis. Gynecol Oncol 150(1):190–200CrossRefGoogle Scholar
  9. 9.
    Quinn MA, Benedet JL, Odicino F, et al. (2006) Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(S1):S43–103CrossRefGoogle Scholar
  10. 10.
    Kim TH, Kim MH, Kim BJ, et al. (2017) Prognostic importance of the site of recurrence in patients with metastatic recurrent cervical cancer. Int J Radiat Oncol 98(5):1124–1131CrossRefGoogle Scholar
  11. 11.
    Fulcher AS, O’Sullivan SG, Segreti EM, Kavanagh BD (1999) Recurrent cervical carcinoma: typical and atypical manifestations. RadioGraphics 19(S1):S103–S116CrossRefGoogle Scholar
  12. 12.
    Son H, Kositwattanarerk A, Hayes MP, et al. (2010) PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics 30(5):1251–1268CrossRefGoogle Scholar
  13. 13.
    Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, et al. (1997) A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 38(3):561–568CrossRefGoogle Scholar
  14. 14.
    Boussios S, Seraj E, Zarkavelis G, et al. (2016) Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol Hematol 108:164–174CrossRefGoogle Scholar
  15. 15.
    Monk BJ, Huh WK, Rosenberg JA, Jacobs I (2017) Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers? Gynecol Oncol Res Pract 4:7CrossRefGoogle Scholar
  16. 16.
    U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2018) FDA approves first biosimilar for cancer treatment. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm576096.htm. Accessed 18 July 2018
  17. 17.
    FIGO Committee on Gynecologic Oncology (2014) FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 125(2):97–98CrossRefGoogle Scholar
  18. 18.
    Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH (2003) Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 44(3):347–352PubMedGoogle Scholar
  19. 19.
    Tirumani SH, Baez JC, Jagannathan JP, Shinagare AB, Ramaiya NH (2013) Tumor-bowel fistula: what radiologists should know. Abdom Imaging 38(5):1014–1023CrossRefGoogle Scholar
  20. 20.
    Sotto LSJ, Graham JB, Pickren JW (1960) Postmortem findings in cancer of the cervix: an analysis of 108 autopsies in the past 5 years. Am J Obstet Gynecol 80(4):791–794CrossRefGoogle Scholar
  21. 21.
    Choi HJ, Roh JW, Seo SS, et al. (2006) Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 106(4):914–922CrossRefGoogle Scholar
  22. 22.
    Wang H, Li QK, Auster M, Gong G (2018) PET and CT features differentiating infectious/inflammatory from malignant mediastinal lymphadenopathy: a correlated study with endobronchial ultrasound-guided transbronchial needle aspiration. Radiol Infect Dis 5(1):7–13CrossRefGoogle Scholar
  23. 23.
    Sugawara Y, Eisbruch A, Kosuda S, et al. (1999) Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40(7):1125–1131PubMedPubMedCentralGoogle Scholar
  24. 24.
    Jeong YY, Kang HK, Chung TW, Seo JJ, Park JG (2003) Uterine cervical carcinoma after therapy: CT and MR imaging findings. RadioGraphics 23(4):969–981CrossRefGoogle Scholar
  25. 25.
    Badib AO, Kurohara SS, Webster JH, Pickren JW (1968) Metastasis to organs in carcinoma of the uterine cervix. Cancer 21:434–439CrossRefGoogle Scholar
  26. 26.
    Flynn VT, Spurrett BR (1969) Sister Joseph’s nodule. Med J Aust 1:728–730PubMedGoogle Scholar
  27. 27.
    Avdalovic M, Chan A (2004) Thoracic manifestations of common nonpulmonary malignancies of women. Clin Chest Med 25(2):379–390CrossRefGoogle Scholar
  28. 28.
    Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27(4):e43CrossRefGoogle Scholar
  29. 29.
    Martínez-Jiménez S, Rosado-de-Christenson ML, Walker CM, et al. (2014) Imaging features of thoracic metastases from gynecologic neoplasms. Radiographics 34(6):1742–1754CrossRefGoogle Scholar
  30. 30.
    National Comprehensive Cancer Network (2018) Cervical cancer. Version 2.2018. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 18 July 2018
  31. 31.
    Kumar R, Gupta R, Khullar S, et al. (2000) Bone scanning for bone metastasis in carcinoma cervix. J Assoc Phys India 48(8):808–810Google Scholar
  32. 32.
    du Toit JP, Grove DV (1987) Radioisotope bone scanning for the detection of occult bony metastases in invasive cervical carcinoma. Gynecol Oncol 28(2):215–219CrossRefGoogle Scholar
  33. 33.
    Hirnle P, Mittmann KP, Schmidt B, Pfeiffer KH (1990) Indications for radioisotope bone scanning in staging of cervical cancer. Arch Gynecol Obstet 248(1):21–23CrossRefGoogle Scholar
  34. 34.
    Chura JC, Shukla K, Argenta PA (2007) Brain metastasis from cervical carcinoma. Int J Gynecol Cancer 17(1):141–146CrossRefGoogle Scholar
  35. 35.
    Cormio G, Pellegrino A, Landoni F, et al. (1996) Brain metastases from cervical carcinoma. Tumori 82(4):394–396CrossRefGoogle Scholar
  36. 36.
    Piura E, Piura B (2012) Brain metastases from cervical carcinoma: overview of pertinent literature. Eur J Gynaecol Oncol 33(6):567–573PubMedGoogle Scholar
  37. 37.
    Fetcko K, Gondim DD, Bonnin JM, Dey M (2017) Cervical cancer metastasis to the brain: a case report and review of literature. Surg Neurol Int 8:181CrossRefGoogle Scholar
  38. 38.
    Malviya VK, Casselberry JM, Parekh N, Deppe G (1990) Pericardial metastases in squamous cell cancer of the cervix: a report of two cases. J Reprod Med 35(1):49–52PubMedGoogle Scholar
  39. 39.
    Pannu HK, Corl FM, Fishman EK (2001) CT evaluation of cervical cancer: spectrum of disease. Radiographics 21(5):1155–1168CrossRefGoogle Scholar
  40. 40.
    Chuang LT, Temin S, Camacho R, et al. (2016) Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. J Glob Oncol 2(5):311–340CrossRefGoogle Scholar
  41. 41.
    Monk BJ, Tewari KS (2014) Evidence-based therapy for recurrent cervical cancer. J Clin Oncol 32(25):2687–2690CrossRefGoogle Scholar
  42. 42.
    Monk BJ, Sill MW, McMeekin DS, et al. (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649–4655CrossRefGoogle Scholar
  43. 43.
    Tewari KS, Sill MW, Long HJ, et al. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734–743CrossRefGoogle Scholar
  44. 44.
    U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2014) Avastin (bevacizumab). Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf. Accessed 18 July 2018
  45. 45.
    U. S. Food and Drug Administration/Center for Drug Evaluation and Research (2018) FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm. Accessed 18 July 2018
  46. 46.
    Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefGoogle Scholar
  47. 47.
    Rosenberg B, Camp LV, Krigas T (1965) Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 205(4972):698–699CrossRefGoogle Scholar
  48. 48.
    Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3(8):1079–1085CrossRefGoogle Scholar
  49. 49.
    King PD, Perry MC (2001) Hepatotoxicity of chemotherapy. Oncologist 6(2):162–176CrossRefGoogle Scholar
  50. 50.
    Trivedi CD, Pitchumoni CS (2005) Drug-induced pancreatitis: an update. J Clin Gastroenterol 39(8):709–716CrossRefGoogle Scholar
  51. 51.
    Torrisi JM, Schwartz LH, Gollub MJ, et al. (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56CrossRefGoogle Scholar
  52. 52.
    Rohatgi S, Jagannathan JP, Rosenthal MH, et al. (2014) Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know? AJR 203(6):1353–1362CrossRefGoogle Scholar
  53. 53.
    Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan: a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56(1):1–12CrossRefGoogle Scholar
  54. 54.
    Long HJ, Bundy BN, Grendys EC, et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23(21):4626–4633CrossRefGoogle Scholar
  55. 55.
    Pubchem (2018) Topotecan. https://pubchem.ncbi.nlm.nih.gov/compound/60700. Accessed 18 May 2018
  56. 56.
    Rodrigues FG, Dasilva G, Wexner SD (2017) Neutropenic enterocolitis. World J Gastroenterol 23(1):42–47CrossRefGoogle Scholar
  57. 57.
    Maitland ML, Wilcox R, Hogarth DK, et al. (2006) Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 54(2):243–245CrossRefGoogle Scholar
  58. 58.
    Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. RadioGraphics 20(5):1245–1259CrossRefGoogle Scholar
  59. 59.
    Edgerton CC, Gilman M, Roth BJ (2004) Topotecan-induced bronchiolitis. South Med J 97(7):699–701CrossRefGoogle Scholar
  60. 60.
    Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(S6):S3–S6PubMedGoogle Scholar
  61. 61.
    Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M (2015) Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int 2015:413076CrossRefGoogle Scholar
  62. 62.
    Moore DH, Blessing JA, McQuellon RP, et al. (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22(15):3113–3119CrossRefGoogle Scholar
  63. 63.
    Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4S3):1–15PubMedGoogle Scholar
  64. 64.
    Bielopolski D, Evron E, Moreh-Rahav O, et al. (2017) Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother 29(2):113–117CrossRefGoogle Scholar
  65. 65.
    Tamiya A, Naito T, Miura S, et al. (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32(3):1103–1106PubMedGoogle Scholar
  66. 66.
    Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13(8):1065–1071CrossRefGoogle Scholar
  67. 67.
    Morris M, Brader KR, Levenback C, et al. (1998) Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 16(3):1094–1098CrossRefGoogle Scholar
  68. 68.
    Muggia FM, Blessing JA, Method M, et al. (2004) Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 92(2):639–643CrossRefGoogle Scholar
  69. 69.
    Gregory RK, Smith IE (2000) Vinorelbine: a clinical review. Br J Cancer 82(12):1907–1913CrossRefGoogle Scholar
  70. 70.
    Plunkett W, Huang P, Xu YZ, et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4S11):3–10PubMedGoogle Scholar
  71. 71.
    Mutch DG, Bloss JD (2003) Gemcitabine in cervical cancer. Gynecol Oncol 90:S8–S15CrossRefGoogle Scholar
  72. 72.
    Chi D-C, Brogan F, Turenne I, et al. (2012) Gemcitabine-induced pulmonary toxicity. Anticancer Res 32(9):4147–4149PubMedGoogle Scholar
  73. 73.
    Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779–1802CrossRefGoogle Scholar
  74. 74.
    Krill LS, Tewari KS (2015) Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother 16(5):675–683CrossRefGoogle Scholar
  75. 75.
    Tirumani SH, Fairchild A, Krajewski KM, et al. (2015) Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. Radiographics 35(2):455–474CrossRefGoogle Scholar
  76. 76.
    Howard SA, Krajewski KM, Thornton E, et al. (2012) Decade of molecular targeted therapy: abdominal manifestations of drug toxicities—what radiologists should know. AJR 199(1):58–64CrossRefGoogle Scholar
  77. 77.
    Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH (2013) Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR 201(1):W15–W28CrossRefGoogle Scholar
  78. 78.
    Odia Y, Shih JH, Kreisl TN, Fine HA (2014) Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol 120(2):431–440CrossRefGoogle Scholar
  79. 79.
    Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3–6CrossRefGoogle Scholar
  80. 80.
    Singh J, Steward M, Booth T, Mukhtar H, Murray D (2010) Evolution of imaging for abdominal perforation. Ann R Coll Surg Engl 92(3):182–188CrossRefGoogle Scholar
  81. 81.
    Hang XF, Xu WS, Wang JX, et al. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67(6):613–623CrossRefGoogle Scholar
  82. 82.
    Tirumani SH, Jagannathan JP, Shinagare AB, et al. (2013) Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology 13(5):461–467CrossRefGoogle Scholar
  83. 83.
    Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH (2014) Gallbladder complications associated with molecular targeted therapies: clinical and imaging features. Clin Imaging 38(1):50–55CrossRefGoogle Scholar
  84. 84.
    Wolford JE, Tewari KS (2017) Highlights from the gynecologic oncology track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol 28(5):e74CrossRefGoogle Scholar
  85. 85.
    Hollebecque A, Meyer T, Moore KN, et al. (2017) An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 35(15S):5504CrossRefGoogle Scholar
  86. 86.
    Schellens JH, Marabelle A, Zeigenfuss S, et al. (2017) Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol 35:5514CrossRefGoogle Scholar
  87. 87.
    Wolchok JD, Hoos A, O’Day S, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRefGoogle Scholar
  88. 88.
    Naidoo J, Page DB, Li BT, et al. (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391PubMedGoogle Scholar
  89. 89.
    Mekki A, Dercle L, Lichtenstein P, et al. (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91–104CrossRefGoogle Scholar
  90. 90.
    Kim KW, Ramaiya NH, Krajewski KM, et al. (2013) Ipilimumab-associated colitis: CT findings. AJR 200(5):W468–474CrossRefGoogle Scholar
  91. 91.
    Kim KW, Ramaiya NH, Krajewski KM, et al. (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31(4):1071–1077CrossRefGoogle Scholar
  92. 92.
    Alessandrino F, Tirumani SH, Krajewski KM, et al. (2017) Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 72(7):521–533CrossRefGoogle Scholar
  93. 93.
    Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2(12):1607–1616CrossRefGoogle Scholar
  94. 94.
    Gkiozos I, Kopitopoulou A, Kalkanis A, et al. (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol.  https://doi.org/10.1016/j.jtho.2018.04.031 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiology, UH Cleveland Medical CenterCase Western Reserve UniversityClevelandUSA
  2. 2.Department of Radiology, Harvard Medical SchoolMassachusetts General HospitalBostonUSA
  3. 3.Department of Imaging, Harvard Medical SchoolDana Farber Cancer InstituteBostonUSA
  4. 4.Department of Radiology, Harvard Medical SchoolBrigham and Women’s HospitalBostonUSA

Personalised recommendations